Sepia Investment, Anchor Partners, and Sage Investment Trust will exit the company by selling their shares via the Offer-for-Sale route.
Dr Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta, and Ankur Kirtikumar Mehta are the promoters of the company.
The shares of the company are proposed to be listed on the BSE Ltd, Bombay Stock Exchange, and NSE Ltd, National Stock Exchange of India.
The book running lead managers of the issue are JM Financial, IIFL Capital Services, and Kotak Mahindra Capital.
Founded on 27 August 2007, Corona Remedies is one of the well-known pharmaceutical companies involved in the development, manufacturing, and marketing of products. Among the top 30 Indian pharmaceutical market, Corona Remedies has become the 2nd fastest growing company, all due to their exceptional team of doctors and innovative efforts. Corona remedies ranked 30th in the domestic market while ranking the 6th largest company in terms of Women’s healthcare. They are growing in treating problems like heart and diabetes care, pain relief, urology, and more.
In FY24, the company generated revenue of ₹1,014.5 from operations, while the company includes 67 brands.
